Exelixis Inc Restricted Cash, Current
Exelixis Inc (EXEL) had Restricted Cash, Current of $0 as of 2020-01-03, per its 10-K filed 2020-02-25.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Restricted Cash and Investments, Current › Restricted Cash and Cash Equivalent, Current
us-gaap:RestrictedCashCurrent · last filed 2020-02-25
- 2020-01-03: Restricted Cash, Current $0.00.
- 2019-09-27: Restricted Cash, Current $0.00.
- 2019-06-28: Restricted Cash, Current $0.00.
- 2019-03-29: Restricted Cash, Current $0.00.
| Period end | Restricted Cash, Current |
|---|---|
| 2020-01-03 | $0.00 10-K · filed 2020-02-25 |
| 2019-09-27 | $0.00 10-Q · filed 2019-10-30 |
| 2019-06-28 | $0.00 10-Q · filed 2019-07-31 |
| 2019-03-29 | $0.00 10-Q · filed 2019-05-01 |
| 2018-12-28 | $0.00 10-K · filed 2020-02-25 |
| 2018-09-28 | $504.00K 10-Q · filed 2019-10-30 |
| 2018-06-29 | $504.00K 10-Q · filed 2019-07-31 |
| 2018-03-30 | $504.00K 10-Q · filed 2019-05-01 |
| 2017-12-29 | $504.00K 10-K · filed 2020-02-25 |
| 2016-12-30 | $0.00 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |